Can you take Farxiga and Entresto together safely?
Yes, Farxiga (dapagliflozin) and Entresto (sacubitril/valsartan) are often prescribed together for heart failure patients with reduced ejection fraction (HFrEF). Clinical guidelines from the American College of Cardiology and major trials like DAPA-HF and PARADIGM-HF support their combined use, showing additive benefits in reducing hospitalizations and cardiovascular death without prohibitive risks.[1][2]
What do clinical trials show about the combination?
In the DAPA-HF trial, dapagliflozin was tested on top of standard therapy including sacubitril/valsartan (used by 33% of participants), cutting the primary endpoint risk by 26% with no excess discontinuations due to adverse events.[1] Real-world data and post-hoc analyses confirm tolerability, with blood pressure lowering as a common effect but rarely leading to hypotension in monitored patients.[3]
What are the main risks or interactions?
No direct pharmacokinetic interactions exist between the SGLT2 inhibitor Farxiga and the neprilysin inhibitor/ARB Entresto. Key concerns include:
- Enhanced blood pressure reduction, which can cause dizziness or low blood pressure in volume-depleted patients.
- Increased urinary tract infections or dehydration from Farxiga's diuretic effect.
- Rare hyperkalemia or kidney function changes, monitored via regular labs.
Start low doses and titrate under supervision; guidelines recommend this combo as foundational therapy.[2][4]
Who should avoid or use caution with this combo?
Avoid in patients with severe kidney impairment (eGFR <30 mL/min for Farxiga), type 1 diabetes, or history of angioedema (Entresto risk). Use caution in the elderly, those on diuretics, or with low baseline blood pressure. Pregnancy category D for both—contraindicated.[4][5]
How do doctors monitor patients on both?
Routine checks include blood pressure, electrolytes, kidney function (eGFR/creatinine), and weight every 1-4 weeks initially, then quarterly. Patient education on hydration, infection signs, and ketoacidosis symptoms is standard.[2]
Are there alternatives if the combo isn't suitable?
For HFrEF, options include swapping to other SGLT2 inhibitors like Jardiance (empagliflozin) or ARNI alternatives like vericiguat. Triple therapy with beta-blockers and mineralocorticoid antagonists remains core regardless.[2]
[1] DAPA-HF Trial (NEJM, 2019)
[2] ACC/AHA Heart Failure Guidelines (2022)
[3] FDA Label: Farxiga
[4] FDA Label: Entresto
[5] Drugs.com Interaction Checker